Clinical Trial Update: BCL2i CLAG-M in R/R Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating a BCL-2 inhibitor in combination with the CLAG-M regimen for relapsed or refractory acute myeloid leukemia and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BCL-2 inhibitor

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Status: RECRUITING